Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;42(12):756-763.

Clinical Practice Updates in the Management Of Immune Thrombocytopenia

Ayesha M Khan, Halina Mydra, Ana Nevarez

Clinical Practice Updates in the Management Of Immune Thrombocytopenia

Ayesha M Khan et al. P T. 2017 Dec.

Abstract

Immune thrombocytopenia (ITP), previously called idiopathic thrombocytopenia purpura, is an autoimmune disorder characterized by a severe reduction in peripheral blood platelet count. In healthy individuals, normal platelet count ranges from 150-450 × 109/L, while in thrombocytopenia counts fall to less than 100 × 109/L.1 In adults, the incidence of ITP is approximately two to four per 100,000.2,3 Bleeding risks, specifically hemorrhage and intracranial hemorrhage, represent the most serious complications for patients with ITP. Over the past decade, the understanding of ITP has expanded greatly, which has contributed to a number of updates in the diagnosis and treatment of the disorder.3 This article aims to briefly review the pathophysiology of ITP and summarize updates in ITP management and treatment options in the adult population.

Keywords: corticosteroids; idiopathic thrombocytopenia purpura; immune thrombocytopenia; immunoglobulin; platelets.

PubMed Disclaimer

Conflict of interest statement

Disclosures: The authors report no commercial or financial interests in regard to this article.

References

    1. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–186. - PubMed
    1. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia (ITP) Blood. 2017;129(21):2829–2835. - PMC - PubMed
    1. Abadi U, Yarchovsky-Dolberg O, Ellis MH. Immune thrombocytopenia: recent progress in pathophysiology and treatment. Clin Appl Thromb Hemost. 2015;21:397–404. - PubMed
    1. Nugent D, McMillan R, Nichol JL, et al. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009;146:585–596. - PubMed
    1. Godeau B. Immune thrombocytopenic purpura: major progress in knowledge of the pathophysiology and the therapeutic strategy, but still a lot of issues. Presse Med. 2014;43(4 pt 2):e47–e48. - PubMed

LinkOut - more resources